Important pharmacy news and late-breaking industry information updated daily.

HHS Secretary Alex Azar says it is within his agency's power to eliminate rebates on prescription drug purchases, asserting they create a perverse incentive to continuously raise drug prices. HHS last month proposed regulations that would scale back protections for rebates that might otherwise be illegal under a federal anti-kickback law.

FDA approved on Thursday the first generic version of the EpiPen and EpiPen Jr. auto-injector for the emergency treatment of allergic reactions, including anaphylaxis, in adults and pediatric patients who weigh more than 33 pounds. Made by Teva Pharmaceuticals USA, the generic epinephrine auto-injector was approved in 0.3 mg and 0.15 mg strengths.

These agents could serve as safe alternatives to warfarin

FDA Commissioner Scott Gottlieb reports the agency is releasing "important information for veterinarians to ensure they have additional context regarding the potential for people to misuse the products that they are prescribing to their animal patients." Among the recommendations for veterinarians is a reminder "about the importance of following al

The Ohio Department of Medicaid on Tuesday indicated it will end the state's contracts with PBMs that bill taxpayers more than they reimburse pharmacists for filling Medicaid patients' prescriptions.

Findings support FDA’s removal of black box warning for ICS/LABA combination inhalers

After two proxy-advisory firms recommended that shareholders back the proposed merger of Cigna and Express Scripts, billionaire activist investor Carl Icahn said Monday that he has dropped his plan to solicit votes from Cigna shareholders against the $54 billion deal.

CDC: Rates quadrupled in 15 years, more prevention, screening, and treatment needed

FDA has approved patisiran (Onpattro—Alnylam Pharmaceuticals) infusion for the treatment of peripheral nerve disease caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. This is the first FDA-approved treatment for individuals with polyneuropathy caused by hATTR.

A new CDC analysis reveals that the number of pregnant women with opioid use disorder (OUD) at labor and delivery more than quadrupled from 1999 to 2014.